Advertisement

Rheumatology International

, Volume 33, Issue 5, pp 1193–1199 | Cite as

A study on anti-mannose binding lectin (anti-MBL) antibodies and serum MBL levels in Indian systemic lupus erythematosus patients

  • Vandana PradhanEmail author
  • Gauri Mahant
  • Anjali Rajadhyaksha
  • Prathamesh Surve
  • Vinod Rajendran
  • Manisha Patwardhan
  • Anita Nadkarni
  • Shruti Dighe
  • Kanjaksha Ghosh
Original Article

Abstract

Systemic lupus erythematosus (SLE) is a prototype autoimmune disease characterized by systemic inflammation and autoantibody production. Anti-mannose binding lectin (anti-MBL) autoantibodies have been studied in SLE for their possible effect on mannose binding lectin (MBL) levels and functional activity. This study aimed at the detection of anti-MBL autoantibodies in Indian SLE patients and evaluates their relationship with related immunological parameters. Two hundred diagnosed SLE patients from Western India were included in the study where 87 patients were lupus nephritis (LN) (43.5 %) and remaining (56.5 %) were non-LN. Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Anti-MBL autoantibodies to IgG and IgM isotypes, anti-C1q autoantibodies, MBL levels and circulating immune complex levels were detected by ELISA. C3, C4 and CRP levels were detected by nephelometer. Anti-MBL autoantibodies were detected in 52 % SLE patients, where 55 % had IgG-anti-MBL, 33.8 % had IgM-anti-MBL and 11.3 % had both subclasses. Low MBL levels were present in 64.4 % anti-MBL positives as compared to 61.5 % in anti-MBL negatives. Among anti-MBL positives, 74 % had anti-C1q antibodies, whereas 41.7 % of anti-MBL negatives had anti-C1q autoantibodies (p = 3.45E06). An inverse correlation was observed between serum MBL and CIC levels. A statistically significant difference was noted between anti-MBL positives and anti-MBL negative patients with hsCRP levels (p = 0.002). Occurrence of infections was higher among anti-MBL positives (65 %) as compared to anti-MBL negatives (35 %). The difference between SLEDAI scores among anti-MBL-positive and anti-MBL-negative groups was statistically insignificant. Anti-MBL autoantibodies in SLE patients can influence functional activity of MBL and have a significant role in SLE disease pathogenesis.

Keywords

Anti-mannose binding lectin (anti-MBL) autoantibodies MBL deficiency Anti-C1q autoantibodies C-reactive protein C3 C4 Lupus nephritis (LN) 

Notes

Acknowledgments

We are grateful to the Director General, Indian Council of Medical Research for allowing us to conduct this study in Indian SLE patients, and we thank Department of Biotechnology (DBT), Government of India for the financial support.

References

  1. 1.
    Shoenfeld Y, Szyper-Kravitz M, Witte T, Doria A, Tsutsumi A, Tatsuya A et al (2007) Autoantibodies against protective molecules—C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1 prevalence in systemic lupus erythematosus. Ann NY Acad Sci 1108:227–239PubMedCrossRefGoogle Scholar
  2. 2.
    Turner MW, Hamvas RM (2000) Mannose-binding lectin: structure, function, genetics and disease associations. Rev Immunogenet 2:305–322PubMedGoogle Scholar
  3. 3.
    Lu JH, Thiel S, Wiedemann H, Timpl R, Reid KB (1990) Binding of the pentamer/hexamer forms of mannan-binding protein to zymosan activates the proenzyme C1r2C1s2 complex, of the classical pathway of complement, without involvement of C1q. J Immunol 144:2287–2294PubMedGoogle Scholar
  4. 4.
    Dahl MR, Thiel S, Matsushita M, Fujita T, Willis AC, Christensen T, Vorup-Jensen T, Jensenius JC (2001) MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity 15:127–135PubMedCrossRefGoogle Scholar
  5. 5.
    Wong N, Sim RB (1997) Comparison of the complement system protein complexes formed by C1q and MBL. Biochem Soc Trans 25(1):41SPubMedGoogle Scholar
  6. 6.
    Kelley JM, Edberg JC, Kimberley RP (2010) Pathways: strategies for susceptibility genes in SLE. Autoimmun Rev 9:473–476PubMedCrossRefGoogle Scholar
  7. 7.
    Monticielo OA, Mucenic T, Xavier RM, Brenol JCT, Chies JAB (2008) The role of mannose-binding lectin in systemic lupus erythematosus. Clin Rheumatol 27:413–419PubMedCrossRefGoogle Scholar
  8. 8.
    Pradhan V, Surve P, Ghosh K (2010) Mannose binding lectin (MBL) in autoimmunity and its role in systemic lupus erythematosus (SLE). J Assoc Physicians India 58:688–690PubMedGoogle Scholar
  9. 9.
    Saevarsdottir S, Steinsson K, Ludviksson BR, Grondal G, Valdimarsson H (2007) Mannan-binding lectin may facilitate the clearance of circulating immune complexes—implications from a study on C2-deficient individuals. Clin Exp Immunol 148:248–253PubMedCrossRefGoogle Scholar
  10. 10.
    Takahashi R, Tsutsumi A, Ohtani K, Goto D, Matsumoto I, Ito S et al (2004) Anti-mannose binding lectin antibodies in sera of Japanese patients with systemic lupus erythematosus. Clin Exp Immunol 136:585–590PubMedCrossRefGoogle Scholar
  11. 11.
    Schwaeble W, Dahl MR, Theil S, Stover C, Jensenius JC (2002) The mannan-binding lectin associated serine proteases (MASPs) and Map19: four components of the lectin pathway activation complex encoded by two genes. Immunobiology 205:455–466PubMedCrossRefGoogle Scholar
  12. 12.
    Hockberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthr Rheum 40:1725CrossRefGoogle Scholar
  13. 13.
    Bombardier C, Gladmsn FF, Urowit MB, Caron D, Chang CH (1995) Derivation of SLEDAI: a disease activity index for lupus patients. The committee on prognosis studies in SLE. Arch Rheum 35:630–640CrossRefGoogle Scholar
  14. 14.
    Weening JJ, Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15(2):241–250PubMedCrossRefGoogle Scholar
  15. 15.
    Mok MY, Jack DL, Lau CS, Fong DYT, Turner MW, Isenberg DA et al (2004) Antibodies to mannose binding lectin in patients with systemic lupus erythematosus. Lupus 13:522–528PubMedCrossRefGoogle Scholar
  16. 16.
    Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y (2004) Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthr Rheum 34:501–537CrossRefGoogle Scholar
  17. 17.
    Seelen MA, Trouw LA, Van der Hoorn JWA, Fallaux-Van den Houten FC, Huizinga TWJ, Daha MR et al (2003) Autoantibodies against mannose-binding lectin in systemic lupus erythematosus. Clin Exp Immunol 134:335–343PubMedCrossRefGoogle Scholar
  18. 18.
    Daha MR (2008) Pathogenic role of auto-antibodies against complement components in systemic lupus erythematosus. Lupus 17:385–388PubMedCrossRefGoogle Scholar
  19. 19.
    Marto N, Bertolaccini ML, Calabuig E, Hughes GR, Khamashta MA (2005) Anti-C1q antibodies in nephritis: correlation between titers and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 64:444–448PubMedCrossRefGoogle Scholar
  20. 20.
    Selander B, Martensson U, Weintraub A, Holmström E, Matsushita M, Thiel S et al (2006) Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J Clin Invest 116:1425–1434PubMedCrossRefGoogle Scholar
  21. 21.
    Horak P, Zadrazil J, Ciferska H, Hermanova Z (2009) Antibodies against complement system in SLE and their potential diagnosis utility. Curr Rheumatol Rev 5:58–63CrossRefGoogle Scholar
  22. 22.
    Williams RC Jr, Harmon ME, Burlingame R, Du Clos TW (2005) Studies of serum C-reactive protein in systemic lupus erythematosus. J Rheumatol 32:454–461PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Vandana Pradhan
    • 1
    Email author
  • Gauri Mahant
    • 1
  • Anjali Rajadhyaksha
    • 2
  • Prathamesh Surve
    • 1
  • Vinod Rajendran
    • 1
  • Manisha Patwardhan
    • 1
  • Anita Nadkarni
    • 1
  • Shruti Dighe
    • 2
  • Kanjaksha Ghosh
    • 1
  1. 1.Department of Autoimmune Disorders, National Institute of Immunohaematology, Indian Council of Medical ResearchKing Edward Memorial HospitalParel, MumbaiIndia
  2. 2.Department of MedicineKing Edward Memorial HospitalParel, MumbaiIndia

Personalised recommendations